BIRMINGHAM, Ala. – CIRCULOGENE, an innovative molecular diagnostics company transforming precision medicine through rapid delivery of actionable results, announced today that Stephen Unger has joined the company as Chief Financial Officer. Mr. Unger has more than 25 years of financial experience within life sciences through senior roles in investment banking, public accounting and private industry. He previously served as Chief Financial Officer of Quotient Limited, which completed a successful initial public offering in 2014.
“We are pleased to welcome Stephen to our team and are energized by his eagerness to help us drive accelerated growth,” said Mike Mullen, CIRCULOGENE President and CEO. “Steve’s broad financial management and capital markets experience within the diagnostics industry, combined with a track record of corporate finance execution, makes this a perfect fit.”
“I am thrilled to join the talented team of CIRCULOGENE that is clearly making a difference in the lives of cancer patients through the delivery of exceptionally accurate and rapid diagnostic test results,” said Stephen Unger. “CIRCULOGENE’s proprietary process for advanced next-generation sequencing is unique within the liquid biopsy marketplace, requiring just one 4mL tube to complete a full range of genomic testing, enabling faster turnaround times for cancer therapy selection, response monitoring, and disease recurrence assessment.”
Mr. Unger most recently served as a Managing Director of Equity Research at Needham & Company, LLC following the Life Science Tools and Diagnostics sector, where he focused on high-growth companies providing innovative precision medicine solutions to fight cancer. Mr. Unger is a Chartered Financial Analyst, a Certified Public Accountant (inactive) and member of the New York Society of Security Analysts. He holds a Master of Business Administration degree from the University of Chicago Booth School of Business and a Bachelor of Business Administration degree from the University of Wisconsin-Madison.
Transforming precision medicine through rapid delivery of actionable results, CIRCULOGENE provides comprehensive biomarker testing for a broad range of cancers, allowing physicians to match patient results with specific therapies (or clinical trials) in just one week. The company has developed proprietary next-generation sequencing (NGS) and qPCR methods that provide a full genomic load analysis, enabling greater data accuracy to help clinicians select targeted therapies, monitor efficacy and assess recurrence for cancer patients. Applying proprietary liquid biopsy innovation for cfDNA and cfRNA—including PD-L1 and MSI detection— CIRCULOGENE can detect circulating germline and somatic mutations and RNA fusions all from a single 4mL tube of blood, tailoring targeted therapy and immunotherapy without delay.
CIRCULOGENE is a Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) certified laboratory and a Verified Vendor for the federal System for Award Management. For more information, visit our website, connect with us on LinkedIn, Facebook and Twitter, or email us at email@example.com or call 855-614-7083. Clinicians interested in ordering tests may visit the Contact page on CIRCULOGENE’s website.